Clinical trialNCT04677777CompletedPhase 1Interventional

Safety Study of PP-007 in Subjects With Acute Ischemic Stroke

SponsorProlong PharmaceuticalsEnrollment24Acute Ischemic Stroke

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collateral flow, infarct size and functional outcomes will be evaluated.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kirsten Gruis, MD
Prolong Pharmaceuticals, LLC
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Baptist Health Research Institute
Jacksonville, Florida, United States
Baptist Health Miami Cardiac & Vascular Institute (mcvi)
Miami, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Saint Luke'S Hospital
Kansas City, Missouri, United States
Mercy Health - St. Vincent Medical Center
Toledo, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Oregon Stroke Center at Oregon Health & Science University (ohsu)
Portland, Oregon, United States
Upmc Stroke Institute
Pittsburgh, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PP-007 + SOC

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Apr 2024
Primary completion: 20 Feb 2025
Completion: 20 Feb 2025
Last update posted: 14 Nov 2025
Registered enrollment: 24
Registry id: NCT04677777

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.